CoreCap Advisors’s vTv Therapeutics VTVT Stock Holding History

CoreCap Advisors’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.69K	Hold	45	–	–	﹤0.01%	2581
2026 Q1	$1.78K	Hold	45	–	–	﹤0.01%	2441
2025 Q4	$1.8K	Hold	45	–	–	﹤0.01%	2498
2025 Q3	$1.05K	Hold	45	–	–	﹤0.01%	2476
2025 Q2	$675	Hold	45	–	–	﹤0.01%	2472
2025 Q1	$779	Buy	+45	New	+$752	﹤0.01%	2579
2022 Q4	$249	Buy	+9	New	+$298	﹤0.01%	2253

Other funds holding VTVT

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

VNA

Valley National Advisers Bethlehem, Pennsylvania $900M AUM 31.19% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

CoreCap Advisors's VTVT Position: Q2 2026 in Review

CoreCap Advisors held its vTv Therapeutics (VTVT) position steady in Q2 2026 at 45 shares worth $1.69K. The position accounts for ﹤0.01% of the portfolio, ranked #2581.

CoreCap Advisors first reported a position in VTVT in Q4 2022 and has held it in 7 quarters since. The position peaked at $1.8K in Q4 2025. 6 funds tracked by Wall St. Rank hold VTVT as of Q2 2026.

CoreCap Advisors held 45 shares of vTv Therapeutics worth $1.69K as of Q2 2026.
CoreCap Advisors left its vTv Therapeutics share count unchanged in Q2 2026.
vTv Therapeutics made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2581 holding.
CoreCap Advisors first reported a position in vTv Therapeutics in Q4 2022 and has held it in 7 quarters since.
CoreCap Advisors's vTv Therapeutics position peaked at $1.8K in Q4 2025.
6 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.